GCT02
/ Myrio Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 10, 2023
Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma.
(PubMed, Clin Transl Immunology)
- "Here, we show our de novo generated, high-affinity EGFRvIII-specific CAR; GCT02, demonstrating curative efficacy in human orthotopic glioblastoma models...This study demonstrates the preclinical functionality of a highly specific CAR targeting EGFRvIII on human cells. This CAR could be an effective treatment for glioblastoma and warrants future clinical investigation."
CAR T-Cell Therapy • Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • EGFR
1 to 1
Of
1
Go to page
1